Targeting the SR-A1-c-Myc axis to augment cardiac resident reparative macrophage proliferation may be a promising therapeutic strategy for doxorubicin-induced cardiomyopathy.
The SR-A1-c-Myc axis may represent a promising target to treat DiCM through augmentation of cardiac resident reparative macrophage proliferation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: